EMA Validates Roche's Marketing Authorization Application for Risdiplam

17 August 2020 / Posted in: Treatments & Research

This begins the formal scientific evaluation process by EMA’s CHMP. It gives the green light for the compassionate use eligibility criteria in the UK to include patients who have SMA Type 1 and Type 2 who have exhausted all therapeutic options, or patients who have SMA Type 1 and Type 2 who have had their treatment interrupted as a direct result of the COVID-19 pandemic.

Read full story

Motability - One Big Day Online

14 August 2020 / Posted in: Information, Support

Motability's 2020 One Big Day events have had to be cancelled due to Covid-19. However, on 10th September, they are hosting a One Big Day Online event through their Facebook page.

Read full story

Share Your Views on Care Coordination for Rare Conditions

14 August 2020 / Posted in: Information, Support

Researchers at University College London are looking for participants for a study which looks at how care of people who have rare conditions is coordinated in the UK, and how patients and healthcare professionals who treat rare conditions would like them to be coordinated.

Read full story

Webinar Recordings

12 August 2020 / Posted in: Information, Support

As part of Community Connections, leading health professionals talked with Martyn Sibley about the impact of Covid-19 on access to nusinersen treatment for children and adults, in three webinars held between July and August. You can now watch them on our website.

Read full story

Data Breach

11 August 2020 / Posted in: Information

We've been advised by Blackbaud, that between Feb and May, a copy of the data we hold about people who have contact with us had been involved in the ransomware attack that affected many charities and organisations. Please be assured all copied data was destroyed before it could be passed on further or misused and that we have strict data security procedures.

Read full story

Risdiplam Approved for the Treatment of SMA in the U.S.

10 August 2020 / Posted in: Treatments & Research

Roche has advised us, as members of SMA Europe, that the U.S. Food and Drug Administration (FDA) has approved risdiplam for the treatment of 5q SMA in adults and children 2 months of age and older. In the U.S., Risdiplam's brand name is Evrysdi™.

Read full story

Distance Aware Campaign

07 August 2020 / Posted in: Information, Support

Distance Aware is an NHS initiative that has been established to explore the concept of polite prompting of social distancing, by means of self-identifying with a badge or similar. This is to help with increased anxiety of many who feel vulnerable, the virus still being present in our communities, and the shielding period coming to an end.

Read full story

UK SMA Research Online Conference - Save the Date!

04 August 2020 / Posted in: Treatments & Research

Taking place on 10th & 11th September, a committee of UK-based PhD students have got together to organise this event with the aim of giving early career researchers an opportunity to present their work. Find out how to submit work for presentation and / or how to join the conference.

Read full story

Disabled Motoring UK - Baywatch Survey 2020

04 August 2020 / Posted in: Information, Support

DMUK are asking individuals to think back over the last 12 months to consider their general parking experience - this data will help tackle the supermarkets and other parking providers over their disabled parking policies. Survey closes end of August.

Read full story

Catalyst Pharmaceuticals Completes Enrolment for a Study of Amifampridine Phosphate in Ambulatory Patients who have SMA Type 3

03 August 2020 / Posted in: Treatments & Research

This biopharmaceutical company, focused on developing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, is evaluating a neuronal potassium channel blocker, for the treatment of SMA.

Read full story